Cargando…

Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery()()

BACKGROUND: Altered enteroendocrine hormone responses are widely believed to underlie the beneficial effects of bariatric surgery in type 2 diabetes. While elevated postprandial glucagon-like peptide-1 (GLP-1) is considered one of the mediators, increased postprandial glucagon levels have recently b...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberts, Geoffrey P., Kay, Richard G., Howard, James, Hardwick, Richard H., Reimann, Frank, Gribble, Fiona M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191023/
https://www.ncbi.nlm.nih.gov/pubmed/29548882
http://dx.doi.org/10.1016/j.soard.2018.01.039
_version_ 1783363654561824768
author Roberts, Geoffrey P.
Kay, Richard G.
Howard, James
Hardwick, Richard H.
Reimann, Frank
Gribble, Fiona M.
author_facet Roberts, Geoffrey P.
Kay, Richard G.
Howard, James
Hardwick, Richard H.
Reimann, Frank
Gribble, Fiona M.
author_sort Roberts, Geoffrey P.
collection PubMed
description BACKGROUND: Altered enteroendocrine hormone responses are widely believed to underlie the beneficial effects of bariatric surgery in type 2 diabetes. While elevated postprandial glucagon-like peptide-1 (GLP-1) is considered one of the mediators, increased postprandial glucagon levels have recently been implicated. OBJECTIVES: We investigated hormonal responses in lean patients after prophylactic total gastrectomy (PTG), as a model of Roux-en-Y gastric bypass without the confounding effects of obesity or massive weight loss. SETTING: University hospital, United Kingdom. METHODS: Ten participants after PTG and 9 healthy volunteers were recruited for oral glucose tolerance tests. Plasma glucose, insulin, GLP-1, peptide YY, glucose-dependent insulinotropic-polypeptide, glucagon, oxyntomodulin, glucagon((1-61)), and glicentin levels were assessed using immunoassays and/or mass spectrometry. RESULTS: PTG participants exhibited accelerated plasma glucose appearance, followed, in 3 of 10 cases, by hypoglycemia (<3 mM glucose). Plasma GLP-1, peptide YY, glucose-dependent insulinotropic-polypeptide, glicentin, and oxyntomodulin responses were elevated, and glucagon appeared to rise in PTG participants when measured with a glucagon-specific enzyme-linked immunosorbent assay. We revisited the specificity of this assay, and demonstrated significant cross-reactivity with glicentin and oxyntomodulin at concentrations observed in PTG plasma. Reassessment of glucagon with the same assay using a modified protocol, and by liquid chromatography-mass spectrometry, demonstrated suppression of glucagon secretion after oral glucose tolerance tests in both PTG and control cohorts. CONCLUSIONS: Care should be taken when assessing glucagon levels in the presence of elevated plasma levels of other proglucagon products. Substantial elevation of GLP-1 and insulin responses after PTG likely contribute to the observed hypoglycemia, and mirror similar hormone levels and complications observed in bariatric weight loss patients.
format Online
Article
Text
id pubmed-6191023
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-61910232018-11-01 Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery()() Roberts, Geoffrey P. Kay, Richard G. Howard, James Hardwick, Richard H. Reimann, Frank Gribble, Fiona M. Surg Obes Relat Dis Article BACKGROUND: Altered enteroendocrine hormone responses are widely believed to underlie the beneficial effects of bariatric surgery in type 2 diabetes. While elevated postprandial glucagon-like peptide-1 (GLP-1) is considered one of the mediators, increased postprandial glucagon levels have recently been implicated. OBJECTIVES: We investigated hormonal responses in lean patients after prophylactic total gastrectomy (PTG), as a model of Roux-en-Y gastric bypass without the confounding effects of obesity or massive weight loss. SETTING: University hospital, United Kingdom. METHODS: Ten participants after PTG and 9 healthy volunteers were recruited for oral glucose tolerance tests. Plasma glucose, insulin, GLP-1, peptide YY, glucose-dependent insulinotropic-polypeptide, glucagon, oxyntomodulin, glucagon((1-61)), and glicentin levels were assessed using immunoassays and/or mass spectrometry. RESULTS: PTG participants exhibited accelerated plasma glucose appearance, followed, in 3 of 10 cases, by hypoglycemia (<3 mM glucose). Plasma GLP-1, peptide YY, glucose-dependent insulinotropic-polypeptide, glicentin, and oxyntomodulin responses were elevated, and glucagon appeared to rise in PTG participants when measured with a glucagon-specific enzyme-linked immunosorbent assay. We revisited the specificity of this assay, and demonstrated significant cross-reactivity with glicentin and oxyntomodulin at concentrations observed in PTG plasma. Reassessment of glucagon with the same assay using a modified protocol, and by liquid chromatography-mass spectrometry, demonstrated suppression of glucagon secretion after oral glucose tolerance tests in both PTG and control cohorts. CONCLUSIONS: Care should be taken when assessing glucagon levels in the presence of elevated plasma levels of other proglucagon products. Substantial elevation of GLP-1 and insulin responses after PTG likely contribute to the observed hypoglycemia, and mirror similar hormone levels and complications observed in bariatric weight loss patients. Elsevier 2018-05 /pmc/articles/PMC6191023/ /pubmed/29548882 http://dx.doi.org/10.1016/j.soard.2018.01.039 Text en © 2018 American Society for Metabolic and Bariatric Surgery. All rights reserved. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Roberts, Geoffrey P.
Kay, Richard G.
Howard, James
Hardwick, Richard H.
Reimann, Frank
Gribble, Fiona M.
Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery()()
title Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery()()
title_full Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery()()
title_fullStr Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery()()
title_full_unstemmed Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery()()
title_short Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery()()
title_sort gastrectomy with roux-en-y reconstruction as a lean model of bariatric surgery()()
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191023/
https://www.ncbi.nlm.nih.gov/pubmed/29548882
http://dx.doi.org/10.1016/j.soard.2018.01.039
work_keys_str_mv AT robertsgeoffreyp gastrectomywithrouxenyreconstructionasaleanmodelofbariatricsurgery
AT kayrichardg gastrectomywithrouxenyreconstructionasaleanmodelofbariatricsurgery
AT howardjames gastrectomywithrouxenyreconstructionasaleanmodelofbariatricsurgery
AT hardwickrichardh gastrectomywithrouxenyreconstructionasaleanmodelofbariatricsurgery
AT reimannfrank gastrectomywithrouxenyreconstructionasaleanmodelofbariatricsurgery
AT gribblefionam gastrectomywithrouxenyreconstructionasaleanmodelofbariatricsurgery